CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 116 enrolled
Drug / intervention
Behavioral Activation +1 morebehavioral
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04036136
NCT04036136N/ACompleted

Development of a Novel Transdiagnostic Intervention for Anhedonia - R33 Phase

University of North Carolina, Chapel Hill·interventional·Posted Jul 29, 2019·Updated Jun 21, 2024

In Brief

A clinical study evaluating Behavioral Activation and Mindfulness Treatment for Anhedonia. Completed, enrolled 116 participants across 1 site.

Detailed Summary

The overall goal of this project is to develop a novel transdiagnostic treatment for anhedonia, called Behavioral Activation Treatment for Anhedonia (BATA), using ultra-high field functional neuroimaging. There is a critical need for a validated treatment that specifically targets anhedonia, and this project will evaluate the effects of this new treatment on anhedonia and will establish how this treatment impacts brain systems that mediate reward processing, clinical symptoms of anhedonia, functional outcomes, and behavioral indices of reward processing. This work will also identify brain targets by which future novel anhedonia treatment may be evaluated.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnhedonia
CountriesUnited States

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedJul 29, 2019
Enrollment StartAug 1, 2019
Primary CompletionJul 31, 2023
TodayJul 2, 2026
Enrollment to primary: 4 yearsPosted 6.9 years ago

Interventions

Behavioral Activationbehavioral

Treatment will consist of 15 weekly 45-minute sessions.

Mindfulness Treatmentbehavioral

Treatment will consist of 15 weekly 45-minute sessions.